Drug Profile

Nurandociguat - Bayer

Alternative Names: BAY-3283142; sGC Activator 4 - Bayer

Latest Information Update: 05 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bayer
Class Antihypertensives; Cardiovascular therapies; Hepatoprotectants; Urologics
Mechanism of Action Guanylate cyclase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Phase II Renal failure
Phase I Cardiovascular disorders; Diabetic retinopathy; Hypertension; Liver disorders

27 Jan 2026 Bayer plans a phase I trial for Coronary artery disease and Kidney disorders in Germany, in March 2026 (CTIS2025-522335-34-00) (EUCT2025-522335-34-00)
21 Nov 2025 Bayer completes phase I clinical trials in Hypertension (Treatment-experienced) in Germany (PO) (NCT06428825) (EudraCT-2024-512060-58-00)
12 Nov 2025 Bayer plans a phase I trial for Hypertension and Renal failure in Germany (EudraCT2025-522336-14-00)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com